Covalent modification of amino acids in proteins is a posttranslation mechanism that alters the proteome, changing the structure of individual proteins and thus potentially affecting their activity, stability, localization and/or binding partners [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . In response to changing conditions during development or in the environment, post-translational protein modification can much more rapidly alter the activity of the proteome compared with transcriptional or translational control mechanisms 4, 14, [19] [20] [21] . Although numerous protein modifications are known, for example, histone methylation and acetylation, the most widely studied modification is phosphorylation. Protein kinasemediated phosphorylation of substrates is the output of a number of signaling pathways (e.g., Ras-extracellular signal-related kinase (ERK)/mitogen-activated protein (MAP) kinase signaling 13, 15 ) and is often part of the molecular mechanism for execution of the signaling cascade and its modulation (e.g., Wnt signaling) 22 . Mass spectrometry has revolutionized our ability to identify posttranslationally modified proteins, through the identification of the modified residue and the surrounding amino acid sequence in which it is embedded 16, [23] [24] [25] [26] . Once a modification site has been identified, antibodies can be generated that specifically recognize the modified protein (modified residue plus surrounding amino acids) 27, 28 . Such modified protein-specific antibodies can be used in a wide range of in vivo studies of the modified protein, some of which are not easily performed by other approaches, such as mass spectrometry 27, 28 . The modified protein-specific antibodies allow immunocytochemical analysis of the modified protein at high spatial and temporal resolution. For example, in complex tissues, the modified protein-specific antibodies can identify individual cells or cell types that do or do not contain the modified protein 27, [29] [30] [31] [32] [33] , and, at the single-cell level, individual organelles or subcellular structures that contain the modified protein [32] [33] [34] [35] [36] [37] [38] [39] [40] . Modified protein-specific antibodies can be used in highthroughput RNAi screens 41 or to test hypotheses related to control of a signaling pathway or utilization of the phosphorylated protein [42] [43] [44] [45] . Importantly, modified protein-specific antibodies can be used to purify protein-protein, protein-DNA or protein-RNA complexes that contain the modified protein; a widely used example is the use of antibodies specific to modified histones for analysis of genomic regions that contain the modified histone in chromatin 4, 14, 20, 24, 46, 47 .
IntroDuctIon
Covalent modification of amino acids in proteins is a posttranslation mechanism that alters the proteome, changing the structure of individual proteins and thus potentially affecting their activity, stability, localization and/or binding partners [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . In response to changing conditions during development or in the environment, post-translational protein modification can much more rapidly alter the activity of the proteome compared with transcriptional or translational control mechanisms 4, 14, [19] [20] [21] . Although numerous protein modifications are known, for example, histone methylation and acetylation, the most widely studied modification is phosphorylation. Protein kinasemediated phosphorylation of substrates is the output of a number of signaling pathways (e.g., Ras-extracellular signal-related kinase (ERK)/mitogen-activated protein (MAP) kinase signaling 13, 15 ) and is often part of the molecular mechanism for execution of the signaling cascade and its modulation (e.g., Wnt signaling) 22 . Mass spectrometry has revolutionized our ability to identify posttranslationally modified proteins, through the identification of the modified residue and the surrounding amino acid sequence in which it is embedded 16, [23] [24] [25] [26] . Once a modification site has been identified, antibodies can be generated that specifically recognize the modified protein (modified residue plus surrounding amino acids) 27, 28 . Such modified protein-specific antibodies can be used in a wide range of in vivo studies of the modified protein, some of which are not easily performed by other approaches, such as mass spectrometry 27, 28 . The modified protein-specific antibodies allow immunocytochemical analysis of the modified protein at high spatial and temporal resolution. For example, in complex tissues, the modified protein-specific antibodies can identify individual cells or cell types that do or do not contain the modified protein 27, [29] [30] [31] [32] [33] , and, at the single-cell level, individual organelles or subcellular structures that contain the modified protein [32] [33] [34] [35] [36] [37] [38] [39] [40] . Modified protein-specific antibodies can be used in highthroughput RNAi screens 41 or to test hypotheses related to control of a signaling pathway or utilization of the phosphorylated protein [42] [43] [44] [45] . Importantly, modified protein-specific antibodies can be used to purify protein-protein, protein-DNA or protein-RNA complexes that contain the modified protein; a widely used example is the use of antibodies specific to modified histones for analysis of genomic regions that contain the modified histone in chromatin 4, 14, 20, 24, 46, 47 .
These approaches require that the antibody be specific to the modified protein being investigated. However, modificationspecific antibodies are not straightforward to generate, and widely used antibodies can be nonspecific, recognizing both the modified and unmodified forms of the target protein or identifying other proteins that contain the modified residue. The modENCODE project, designed to identify the distribution of histone modifications genome-wide using chromatin immunoprecipitation (ChIP) analysis, found that nearly 50 of the 200 commonly available antibodies were either not specific to the histone modification or showed reactivity to nonhistone proteins; for example, in the case of regularly used antibodies to H3pS10 (ref. 46) , preparations were found to cross-react with the unmodified form 48 . Unknown are the number of failed attempts by individual laboratories to generate or purify antibodies specific to a modified protein. Thus, there is a need to develop and refine methods that yield very high quality, specific antibodies for detection of post-translational modifications in vivo. Here we present a protocol that allows the purification of highly specific polyclonal antibodies that detect post-translationally modified proteins, which can then be used in multiple distinct assays including immunocytochemistry, western blotting and immunoprecipitation. using a three-part approach: (i) bioinformatic identification of evolutionarily conserved proteins that contain ERK docking sites; (ii) an RNAi screen for enhancement of either a weak loss-offunction mutation in ERK or a weak gain-of-function mutation in Ras; and (iii) quantitative in vitro tests of phosphorylation of the candidate proteins by activated EKR2 (ref. 28) . Although this approach identified high-likelihood substrates, it remained to be demonstrated that the gene products were phosphorylated in vivo by ERK. Therefore, we turned to the generation of phosphoprotein-specific antibodies to the candidate substrates. We used site-directed mutagenesis to map the serine (S) or threonine (T) residue N-terminal to proline (P), which is typically used as the phospho-acceptor for ERK2, in an in vitro kinase assay. We then generated antibodies to a peptide that contained the phosphorylated S or T and surrounding amino acids that were unique to the substrate. We purified phosphoprotein-specific antibodies to candidate substrates DEAD-box RNA helicase 19 (DDX19) and glycogen synthase kinase 3 β (GSK3β) and used the antibodies to show that these gene products are phosphorylated in vivo at the identified sites and that the phosphorylation was dependent on ERK activity, as it failed to occur in a null mutant of mpk-1, the C. elegans ERK ortholog 28 .
The utility of phosphoprotein-specific antibodies, as well as non-phospho-specific antibodies, in studies of modified protein function is illustrated with NOS-3 in Figure 1 . NOS-3, a Nanosrelated RNA-binding protein, was identified as an MPK-1/ERK substrate where phosphorylation disrupts binding to Pumiliorelated cofactors FBF-1/-2, leading to relief of translational repression of the fem-3 mRNA 27 . To understand spatial control of MPK-1 ERK-mediated regulation of fem-3 translation, we generated and purified antibodies specific for phosphorylated NOS-3 (pNOS-3) and nonphosphorylated NOS-3 (non-pNOS-3) proteins. We used western blotting of C. elegans lysates (Fig. 1a) to demonstrate that the anti-pNOS-3 antibody preparation was specific, as it showed a single band in wild type but no staining in extracts from nos-3-null mutant worms (specificity for the NOS-3 protein) and no staining in extracts from mpk-1 ERK-null mutant worms (specificity of the modified site for the kinase). Similarly, we demonstrated that the anti-non-pNOS-3 antibody (Fig. 1b) was specific, as it produced a single band in wild type but no staining in extracts from nos-3-null mutant worms (specificity for NOS-3), whereas a single band was observed in mpk-1-null mutants (specificity to the nonphosphorylated form of NOS-3). By using immunocytochemical staining of the germ-line tissue with the phospho-specific NOS-3 antibodies, we found that only cells containing activated MPK-1/ERK have phosphorylated NOS-3 ( Fig. 1c) and that phosphorylation was genetically dependent on MPK-1 (ref. 27 ). Antibody staining demonstrates that nonphospho-NOS-3 is present only in the region of the germ-line tissue that lacks activated MPK-1/ERK (Fig. 1d) , that phosphoand non-phospho-NOS-3 are present in mutually exclusive accumulation patterns in the germ-line tissue and that the sum of the two patterns is identical to the staining observed for total NOS-3 protein 27 . These results indicate that, in cells with activated MPK-1/ERK, there is essentially complete conversion of NOS-3 to the phosphorylated form that no longer binds to co-regulators FBF-1/-2, thus fully relieving fem-3 translational repression.
In this protocol, we describe the generation of phospho-specific antibodies to the RNA helicase CGH-1, which is orthologous to yeast Dhh1p and human DDX6, to illustrate a number of points in the description of the antibody purification protocol and specificity testing. Interestingly, phosphorylation of CGH-1 causes a change in subcellular localization of the protein, which is detected by immunocytochemical staining with the phospho-specific antibodies (see below).
Overview of the workflow
The protocol describes the generation of polyclonal phosphoprotein-specific antibodies, where we have significant experience with sites phosphorylated by proline-directed S or 
Figure 1 | Spatial control of NOS-3 phosphorylation in the C. elegans germ-line tissue. Phospho-and non-phospho-specific antibodies provide unique reagents that allow the analysis of the spatial distribution of protein modifications that would be difficult or impossible to obtain by other methods. (a,b) The specificity of purified anti-pNOS-3 and purified anti-nonpNOS-3 antibody preparations is shown in a and b, respectively, which are western blots of total lysates from adult wild-type (WT), nos-3-null mutant (nos-3(0)) and mpk-1/ERK-null mutant (mpk-1(0)) worms. Purified antipNOS-3 antibody, raised against the peptide shown in table 2, identifies a single protein species in wild type that is absent in nos-3(0) and in mpk-1(0), which encodes the kinase that generates the modified sites. Purified antinon-pNOS-3 antibody, raised against the peptide in table 2 without the phospho-residues, identifies a single band in wild type and in the absence of the kinase (mpk-1(0)), but it fails to identify a protein species in nos-3(0). Tubulin western blot sample loading control, bottom (a,b).
(c,d) Immunocytochemical staining of wild-type adult hermaphrodite germ lines shows that purified anti-pNOS-3 antibody staining (green in c) is found in proximal germ cells that also contain activated MPK-1/ERK (red, dpMPK-1, in c), whereas purified anti-non-pNOS-3 antibody staining (green in d) is found in a mutually exclusive population of germ cells that lack activated MPK-1 (red, dpMPK-1, in d). The sum of the pNOS-3 and non-pNOS-3 signal is equivalent to total NOS-3 staining 27 . Asterisks (*) indicate the distal end of the germline. TZ, transition zone. Scale bar, 20 µm. Adapted with permission from ref. 27 .
T kinases (p(S/T)P site) such as MAP kinases. The protocol can also be applied to purifying polyclonal antibodies specific to many other protein modifications, as well as standard fusion proteins. The first phase of the procedure is to raise polyclonal antibodies against a peptide that contains the phosphorylation site(s); this polyclonal serum will contain a complex mix that includes antibodies that react specifically to the phosphoprotein of interest, as well as antibodies that react with the nonphosphorylated protein and antibodies that react with low sequence complexity phospho-epitopes ( Table 1) . The protocol uses a subtraction procedure to remove undesired antibodies that react with the nonphosphorylated protein, and an affinity purification procedure to enrich for antibodies that react with the complex phosphopeptide epitope, similar to previously described methods 48, 49 . In practice, however, we find that although a single round of subtraction can be sufficient to remove antibodies that react with the non-phosphopeptide, a single round of affinity purification is, in most cases, insufficient to remove antibodies that react with low sequence complexity phospho-epitopes (see ref. 28) . Therefore, the workflow of the protocol incorporates two methodological approaches to remove undesired antibodies and specificity tests to assess the extent of purification along the way (Fig. 2) . The first approach uses iterative rounds of subtraction and affinity purification to remove undesired antibodies. The second approach uses high-stringency washes to remove antibodies that bind to low sequence complexity phospho-epitopes. After each round, dot-blot and western blot analyses are conducted as specificity tests to determine whether additional rounds of subtraction and/or affinity purification are necessary. Finally, western blotting and/or immunohistochemical staining of phosphoprotein gene product-null mutants or RNAi knockdown samples are used to validate the specificity of the antibody preparation to the phosphoprotein of interest.
Comparison with other methods
Antibodies that specifically recognized protein modifications such as phospho-tyrosine were first described in 1981 by Ross et al. 50 . Polyclonal anti-phospho-tyrosine antibodies were generated by immunization with phospho-tyrosine-modified keyhole limpet hemocyanin (KLH) followed by affinity purification with phospho-tyrosine-modified Sepharose. These purified panphospho-tyrosine antibodies were used to demonstrate that numerous tyrosine-phosphorylated proteins are present in Rous sarcoma virus (RSV)-transformed mammalian cells. Subsequently, Nairn et al. 51 generated antibodies to a phosphorylation site on the protein G substrate by using a phosphopeptide immunogen, and also generated antibodies to the corresponding unphosphorylated site by using a non-phosphopeptide immunogen; the two antibodies were then used to follow the kinetics of G substrate phosphorylation in vitro. These initial studies provided the basis of current methods for purification of phosphoprotein-specific antibodies. Salient features of current methods for purification of polyclonal phosphoprotein-specific antibodies 48, 49, [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] are summarized as follows: (i) immunization with a phosphopeptide corresponding to the phosphorylated region of the protein under study; (ii) purification of the resulting antisera, first through removal of antibodies that react to the nonphosphorylated protein by a single round of subtraction against the nonphosphorylated peptide table 1 | Assortment of antibody reactivity after immunization with phosphopeptide.
antibody reactivity amino acid sequence Description
Peptide immunogen X 1 -X 2 -X 3 -X 4 -p[s/t]-P-X 7 -X 8 -X 9 X 10 -C Conceptual phosphopeptide immunogen used to generate phosphoprotein-specific antibodies and used for affinity purification Non-phosphopeptide X 1 -X 2 -X 3 -X 4 -[S/T]-P-X 7 -X 8 -X 9 X 10 -C The corresponding non-phosphopeptide that is used in the subtraction Desired antibody specificity X 2 -X 3 -X 4 -p[s/t]-P-X 7 -X 8 Desired antibody specificity, which is typically of sufficient sequence complexity to specifically recognize the modified protein and is generated from the peptide immunogen in the first row of this table and the purification workflow outlined in Figure 2 Total protein antibody specificity X 1 -X 2 -X 3 -X 4 P-X 7 -X 8 -X 9 X 10
Total protein antibody specificity, not including the phospho-epitope Antibody specificity to low complexity epitope linked to Sepharose, followed by affinity enrichment for antibodies that react to the phosphorylated protein by a single round of binding the antibody preparation to the phosphopeptide linked to Sepharose; (iii) in the final step, elution and testing of the antibodies bound to the phosphopeptide under various experimental conditions. We and other groups have found that a single round of affinity purification is usually insufficient to obtain polyclonal antibodies that are specific to the phosphorylated protein of interest, as the preparation shows cross-reactivity toward other cellular or organismal proteins (Fig. 3) 28, 49 . The polyclonal antiserum generated after immunization with the phosphopeptide contains a complex mixture including antibodies that recognize the phospho-residue (p(S/T)) plus a number of surrounding amino acids (Table 1) such that the epitopes are of sufficient sequence complexity to uniquely identify, in most cases, a specific protein in an organismal proteome. However, the complex mixture also contains antibodies that recognize the phospho-residue and only one or a few surrounding amino acids (Table 1) , where these epitopes are found on a number of other phosphorylated proteins in an organismal proteome. A single round of affinity purification will enrich for both antibodies that recognize the unique or complex sequence epitope and antibodies that recognize low sequence complexity epitopes, which then bind to and cross-react with other cellular phosphoproteins that contain the low sequence complexity epitopes as part of their phospho-sites, resulting in a preparation that is not specific to the protein of interest. Previous protocols have proposed that the solution to the problem of single-round purified antibodies cross-reacting with other cellular proteins is to repeat the immunization process starting with a new cohort of rabbits and then perform a single round of subtraction and affinity purification 49 . However, antibodies that recognize the lower sequence complexity phospho-epitopes are also likely to be generated in additional immunizations. Instead, this protocol uses iterative cycles of affinity purification (and subtraction, if necessary) and high-stringency (pH 4.0) washes to enrich for antibodies that recognize the unique/complex sequence epitopes and remove antibodies that bind to the low sequence complexity epitopes (as described above).
Monoclonal antibodies specific for a phosphorylation site on the protein of interest are an excellent alternative to purification of polyclonal antibodies for that phosphoprotein. Monoclonal antibodies that are specific to a number of modified proteins have been generated; two widely used examples are the monoclonal antibody to activated ERK 28 and to phosphohistone H3(Ser10) [64] [65] [66] . Distinct advantages of a phosphoproteinspecific monoclonal antibody is that the single complex epitope specificity is defined and preparations are highly uniform leading to reproducible results between laboratories. The generation of phosphoprotein-specific monoclonal antibodies is, however, several fold more expensive than the generation and purification of polyclonal antibodies, and it is time-consuming to screen Steps 83-92
Step 94
Elute bound antibody Step 93 If the antibody fractions react to the non-phosphopeptide
Step 96 If antibodies to total protein and to low sequence complexity epitopes are present
Step Expectations for the size of the phosphoprotein and the number of bands (e.g., if there are multiple isoforms from alternative splicing N terminal and/or C terminal to the phosphorylation site) will be specific to the protein under study; if there are no existing publications on the gene product, then size may be deduced from the protein amino acid length and number of isoforms from ESTs/cDNA sequence and RNA-seq data obtained from databases such as the University of California, Santa Cruz (UCSC) Genome Browser.
among many monoclonal antibody-secreting clones to identify the one that is specific to the phosphoprotein of interest, not cross-reacting with other related lower-sequence-complexity phospho-sites, with no guarantee of a successful outcome. The generation and purification of polyclonal antibodies specific to a phosphoprotein is most useful in the initial characterization phase of a project where the antibody preparation is used to demonstrate that the phosphorylation occurs in vivo, that it occurs through the predicted kinase(s) and is temporal and/or spatially regulated in a biologically interesting way, providing impetus for the generation of a monoclonal antibody. Furthermore, it provides proof of principle that antibodies that recognize an epitope that specifically identifies the phosphoprotein of interest can be produced, supporting the time and expense in the generation of the corresponding monoclonal antibody.
Applications
The protocol has been successfully used to generate a number of phosphoprotein-specific antibodies 27, 28 (S.A., unpublished data, as well as histone H3 methylation-and acetylation-specific antibodies, and thus it should be applicable to any modified amino acid that can be incorporated into a chemically synthesized peptide. We have also used the affinity purification steps to purify polyclonal antibodies to fusion proteins, to detect total FEM-3 (ref. 27 ) and GFP (S.A., unpublished data). In all these cases, two or more rounds of affinity purification were necessary to obtain specific antibodies. Similarly, it is likely that numerous research groups have generated polyclonal antibody preparations that failed to show specificity after having undergone one round of affinity purification, and thus they were assumed not to contain specific antibodies and were discarded or stored unused in freezers. It is possible that such antiserum, after multiple rounds of affinity purification with stringent washes, may generate specific antibodies, resurrecting discontinued lines of investigation. Therefore, the protocol will be useful to obtain specific polyclonal antibodies to modified proteins and to total proteins, by using modified-peptide and peptide or fusion protein immunogens, respectively, from de novo immunizations and potentially from stored frozen antiserum that was thought not to contain specific antibodies.
Limitations
The modified peptide (or the fusion protein) must elicit a strong immune response, usually assessed by ELISA through the custom antibody vendor. It is very difficult to generate a specific antibody preparation from low-titer antiserum. High temporal resolution samples can usually be obtained for immunocytochemistry and used with the modified protein-specific antibody preparation. However, such fixed samples may not allow observation of dynamic molecular behaviors that can be obtained from realtime cytological analysis. There are currently no methods for specifically tracking a modified protein in real time. Sometimes, sequence context of a phospho-epitope is not unique, and this usually occurs when the protein may belong to a gene family. In such situations, it is important to devise extensive specificity controls to ensure that the desired protein is indeed being phosphorylated in vivo and not another family member; often times, these experiments are challenging and difficult to conduct owing to the inherent redundancy in biology.
Experimental design Phosphopeptide design. To be a useful experimental tool, phospho-specific antibodies must specifically bind with high affinity to the phosphorylated protein of interest but not recognize the unphosphorylated form or other phosphorylated proteins. The binding pocket of an antibody can interact with its antigenic determinant (epitope) in the range of up to six to ten amino acids [67] [68] [69] . Six to ten amino acids are of sufficient sequence complexity that they should, in most cases, uniquely identify a specific protein in the proteome of an organism [67] [68] [69] . Because phosphorylation occurs at a specific site(s) in the protein under study, the peptide sequence that is to be used as an immunogen is constrained by this location. BLAST analysis 70 should be performed to determine the uniqueness of this site in the proteome of the relevant organism(s). Typical phosphopeptide immunogens that we have used have a centrally located p(S/T)P site with about four amino acids N terminal and four C terminal to that site ( Table 1) . A cysteine (C) is placed at the N or C terminus for cross-linking the peptide to the carrier proteins for immunization (KLH) and antibody purification (BSA). Table 2 lists examples of peptides that we have used successfully to raise phosphoproteinspecific antibodies. In peptide immunogen design, we have not used N-or C-terminal extensions greater than six amino acids flanking a given side of the p(S/T)P site to avoid excessive generation of antibodies to the total protein, and in some cases shorter lengths were used to avoid cross-reaction with related protein family members or cysteine residues that can form disulfide bonds with the terminal cysteine used in coupling. For MPK-1/ERK substrates GSK3β and NOS-3, in vitro kinase assays and site-directed mutagenesis suggested that two sites were phosphorylated in vivo 27, 28 and were in sufficient proximity that antibodies of high sequence complexity could be generated that simultaneously recognize both modified sites.
Generation of polyclonal antisera. Screening of animals before immunization: we recommend prescreening of the animals to be injected for the generation of the sera against whole-cell extracts of the tissue or cell type of interest. Obtain 1 ml of preimmune sera from the animals to be injected from the vendor, and perform western blot analysis with the sera at 1:1,000 and 1:5,000 against tissue or cell extract of choice. Ideally, the animal to choose for injecting the antigen and generation of the serum should be one that has the least amount of pre-existing response against the tissue or cell extract. Typically, we follow a 10-week immunization schedule for the generation of the antisera, which consists of one priming injection and three biweekly injections and one booster injection followed by the production bleed. Antisera with a low titer to the phosphopeptide will often be difficult to purify. The antibody response to the phosphopeptide can be assayed via ELISA or dot blot before terminal bleeds, usually performed by the vendor. For a given peptide antigen, antibody titers can differ from animal to animal owing to differences in the immune response resulting in differences in the concentration of the various antibodies generated. Typically, ELISA titers are compared between the preimmune serum and the postimmune serum, at dilutions of 1:1,000, 1:10,000 and 1:100,000. A high titer of postimmune sera versus preimmune sera (e.g., 20,000 versus 800) is considered a good sign of response specifically to the antigen injected, at the 1:100,000 dilution, or in terms of OD levels at 280 nm, 0.088 (for preimmune at 1:100,000) to 2.873 (for postimmune, at 1:100,000) are considered good values to proceed with. Usually, these values are an indication that a response has been generated, and thus antibodies can be purified. Refer to the TROUBLESHOOTING section for more information.
Immunization and the various antibody species that are generated. After immunization with the 2 mg of KLH-conjugated phosphopeptide, polyclonal antibodies that have a diverse array of reactivities will be generated, which is shown schematically in Table 1 . These include the following: (i) antibodies with the desired specificity that react with sufficiently complex sequence epitopes, including the p(S/T) residue, such that it uniquely identifies the phosphorylated protein under study and binds with high affinity; (ii) antibodies that react with only flanking residues, but not the p(S/T) residue, and thus may have specificity to the total protein, both the phosphorylated and nonphosphorylated forms; (iii) antibodies that react with the p(S/T) residue and only one or a few surrounding amino acids and thus represent low-sequencecomplexity epitopes that problematically will cross-react with a number of other phosphorylated proteins present in the proteome and should bind the immunogen with lower affinity; and (iv) antibodies that react specifically with the nonphosphorylated form of the protein, which presumably arise from dephosphorylation of the peptide immunogen early after immunization.
Peptide column preparation (Steps 1-46) . Antibodies that specifically bind to the complex sequence phospho-epitope represent a small proportion of the antibodies present in the immune serum, and thus efficient recovery is important. The protocol uses two peptide columns: a non-phosphopeptide column to subtract antibodies that recognize total protein and a phosphopeptide column for affinity purification. A Sepharose bead is typically linked to a single peptide (or protein) [71] [72] [73] . By contrast, a single BSA molecule can have up to nine peptides conjugated through cysteine residues. By first coupling the peptide to BSA and then coupling the peptide-BSA complex to Sepharose, we can obtain an approximately ninefold increase in the number of peptides bound per Sepharose bead, which increases the capacity of the column, and the higher local peptide density may help anchor the antibodies to the beads. The protocol describes the production of the peptide Sepharose columns in two stages. In the first stage (Steps 1-6), homobifunctional maleimide-based chemistry is used to cross-link the added N-or C-terminal cysteine of the phosphopeptide or non-phosphopeptide to maleimide-activated BSA, forming stable thioether linkages. The peptide-BSA complex is then purified by using a desalting column (Steps 7-17), and the efficiency of coupling the peptide to BSA is assessed by SDS-PAGE (Steps 18-22) (Fig. 4) . In the second stage (Steps 26-46), the peptide-BSA complex is coupled to the column matrix with amine-based chemistry 74 , by using cyanogen bromide-activated Sepharose (CNBr-Sepharose). Before coupling, the peptide-BSA complex is dialyzed into a basic pH solution (Steps 23-25) required for the reaction and to remove any amine-based buffers (Tris, EDTA) that will inactivate the CNBr-Sepharose. After coupling, the column is stringently washed with repeated cycles of alkaline buffer and then acidic buffer (Steps 42-44) to eliminate any peptide-BSA complex that is loosely associated with the CNBr-Sepharose through ionic interactions, which would be eluted in the later elution step and then bind to the purified antibody, blocking its activity. Finally, the column is washed with a Tris-based high-salt buffer (blocking buffer) to block any reactive sites that may have remained uncoupled on the Sepharose resin (Steps 45,46). If the affinity purification fails to recover antibodies that recognize the phosphopeptide ( Fig. 2 and table 1 Workflow: subtraction (Steps 47-57) and affinity purification (Steps 58-73). To obtain phosphoprotein-specific antibodies, the protocol involves a subtraction step to remove antibodies that will cross-react with total protein, including the nonphosphorylated form (Table 1) , and an affinity purification step to remove antibodies that will react with low sequence complexity phosphorylation sites (Table 1) , and thus they are not specific to the phosphorylated protein under study. The workflow for the purification is shown in Figure 2 , where the crude antiserum is sequentially passed over two columns (prepared as described above). The first column contains the non-phosphopeptide that will bind and subtract away antibodies that react with the total protein ( Table 1) , whereas antibodies that react with the phosphopeptide will not bind and be present in the flow-through fraction. The second column contains the phosphopeptide and is used for affinity purification. The flow-through fraction from the non-phosphopeptide column contains two distinct populations that associate with the phosphopeptide: antibodies that bind to complex sequence epitopes, at high affinity, that are specific to the phosphoprotein under study ( Table 1 ) and antibodies that bind low sequence complexity epitopes, containing only one or a few residues other than the p(S/T) residue ( Table 1) . Stringent washes are used to remove antibodies that bind the low sequence complexity epitopes, which are expected to bind with lower affinity than those that bind to the complex sequence epitopes. Sequential washes with alkaline (pH 9.5) and acidic (pH 4.0) buffers are performed; the alkaline buffer stabilizes the interaction between the antibody and the phosphopeptide 75, 76 , whereas the acidic (pH 4.0) wash will destabilize the low-affinity antibody interactions with the phosphopeptide resulting in their elution from the column 47, [77] [78] [79] . The stringent alkaline and acidic washes are repeated three or four times in an effort to remove more antibodies with low affinity or low sequence complexity recognition. The antibodies that recognize high-complexity epitopes that bind at high affinity are then eluted with strong acidic conditions, glycine buffer at pH 2.2, and immediately neutralized.
Workflow: specificity testing, iterative rounds of subtraction and affinity purification (Steps 74-96). Two specificity tests are then performed on the preparation that has undergone one round of subtraction and affinity purification. First, we use a simple dot-blot procedure to determine which elution fractions contain IgG activity (Steps 74-82). Alternatively, if a fraction collector is used that is connected to a UV 280-nm readout machine, then the protein reading in the fractions can be automatically visualized, and the fractions in the OD peak can be pooled. By using the dot-blot assay, the eluted antibody is tested for reaction to the phosphopeptide and to the non-phosphopeptide (Steps 83-93; Fig. 5) . If the purified antibody reacts with the non-phosphopeptide, in addition to the phosphopeptide, then antibodies that recognize the total protein ( Table 1 ) remain in the preparation. Thus, to remove the antibodies that recognize the total protein, the preparation must undergo a second round of subtraction, passed again over the non-phosphopeptide column (Fig. 2, g→b) . Second, by using a western blot assay with lysates from wild-type cells or organisms that are undergoing signaling that generates the phosphomodification, the antibody preparation is tested for specificity to the phosphoprotein under study (Steps 94-96; Fig. 3) . If the purified antibody shows western blot bands in addition to the relevant gene product, then the antibody preparation is reacting to other proteins, which contain the p(S/T) site plus one or a few amino acids that are similar to the complex phospho-epitope (Table 1) . Thus, a second round of affinity purification with stringent washes is used to further remove antibodies that react with the lower sequence complexity phospho-epitopes (Fig. 2, h→d) . If antibodies to total protein and to low sequence complexity epitopes are present, then both the subtraction and affinity purification are repeated (Fig. 2, h→b) . In practice, we find that the major impediment to obtaining a phosphoprotein-specific preparation are antibodies that react with the lower sequence complexity phospho-epitopes ( Fig. 3 and Table 1 ) 28 , as also observed by others 49 . Although removal of antibodies that react with the non-phosphoprotein is usually accomplished with one or two rounds of subtraction (Fig. 5) , removal of antibodies against the lower sequence complexity epitopes, as assessed by nonspecific bands on the western blot (Fig. 3) , often requires four rounds of affinity purification with stringent washes (shown for pCGH-1 here and for affinity purification of anti-pDDX-19 antibodies in Supplementary Fig. 3c of ref. 28) . Thus, the use of multiple rounds of affinity purification, with stringent washes and subtractions, is key to obtaining an antibody preparation that is specific to the phosphoprotein of interest.
Genetic-based specificity tests (Step 97).
The gold standard for determining in vivo specificity of the antibody preparation is the genetic-based assay (Figs. 1a and 6) . First, a null mutant or RNAi-mediated depletion of the protein containing the phosphorylation site (CGH-1) is used in western blots (Fig. 6) and/or in immunocytological staining 27 to assess whether the signal from the purified antibody is specific to the protein under study. If the gene product-null or RNAi knockdown show inappropriate bands in a western blot or signal in immunohistochemistry, then Figure 5 | Dot blot to test specificity toward the CGH-1 phosphopeptides and non-phosphopeptides. An amount of 10 ng each for the phospho-and non-phosphopeptide was spotted on nitrocellulose and probed with 1:1,000 dilution of the anti-phospho CGH-1 peptide column eluate (from Fig. 2 ). Row 1 shows that after the first round of antibody purification, the antibody retains residual activity toward the non-phosphopeptide. Row 2 shows that the activity toward the non-phosphopeptide is lost after the second round of purification.
the preparation shows cross-reaction to other gene products or modified proteins and it should undergo an additional round of affinity purification ( Fig. 2, h→d; repeat Steps 58-73). Note that if there is a paralog(s) or homolog(s) with sequence identity in the phosphorylation site and surrounding sequences, as assessed from BLAST analysis, then the expectations for results from western blots and immunocytochemistry of wild-type and null mutants or knockdowns should be modified accordingly, and additional genetics-based experiments may need to be used to assess specificity. Second, if the enzyme that produces the protein modification is known, then RNAi knockdown or a null mutant of the modifying enzyme (e.g., MPK-1-ERK) should reduce or eliminate the signal from the modified protein-specific antibody preparation (pCGH-1) but they should not affect the amount of total protein (Figs. 1 and 6) .
Purification of non-phosphoprotein-specific (Steps 98-103) and total antibodies (Steps 117-142). In some situations, it is useful to generate polyclonal antibodies that are specific for the unmodified non-phosphoprotein (e.g., NOS-3; Fig. 1b,d ) 27 . In this situation, the order of purification is reversed from the workflow shown in Figure 2 . The crude antiserum is first passed over the phosphopeptide column, removing antibodies that react with the phospho-epitopes and total protein ( Table 1) . The flow-through is then passed over the non-phosphopeptide column, washed stringently to remove antibodies to low sequence complexity epitopes, and then eluted. Specificity tests are performed as described above, with non-phosphoprotein specificity being the desired goal 27 (Fig. 1b) . As with purification of the phospho-specific antibody fraction, the non-phospho antibody sometimes also needs to be purified reiteratively. For example, the non-phospho-NOS-3 antibody was purified via subtraction from the phospho fraction followed by affinity purification in three complete cycles, wherein the first cycle consisted of subtraction followed by affinity purification, as did the second and third cycles. In many cases, it is useful to generate antibodies that are specific for total protein (both the modified and unmodified forms) (e.g., total CGH-1; Fig. 6 ). However, antibodies that will react with total protein from the phosphopeptide immunogen (Table 1) are problematic, as they have specificity to shorter peptide sequences and thus they are likely to react with nontarget proteins. Instead, we have used either recombinant fusion protein isolated from Escherichia coli, which will lack eukaryotic modifications, or peptide immunogens that correspond to a separate part of the protein than the region where the modification resides. The protocol describes coupling of the recombinant proteins to Sepharose (Steps 117-130) and affinity purification (Steps 131-142).
Concentration and storage of the purified antibody preparation (Steps 111-116).
Once the purified antibody preparation has passed the relevant specificity tests described above and is ready for use, it should be concentrated to ~1 mg ml −1 and placed into a stabilization buffer (final concentration-2.5% (wt/vol) BSA, 0.01% (vol/vol) Tween-20 and 25% (vol/vol) glycerol). For long-term storage, keep the antibody at -80 °C; however, working stocks can be maintained at 4 °C up to 3 months. A good starting dilution for the final antibody in various applications such as western blotting, immunoprecipitation and immunofluorescence is 1:1,000 (for western blotting), 10-15 µg of antibody per mg of total protein extract for immunoprecipitation and 1:200 for immunofluorescence. However, dilutions should be optimized depending on the results obtained.
Regeneration of columns (Steps 104-110).
For reuse or storage of the columns, either for additional rounds of purification or for first-round purification of crude serum, residual antibodies bound to the column must be eluted and the pH brought back to neutral (to prevent degradation of the peptide-BSA complex coupled to the Sepharose). We have reused columns up to six Figure 6 | Genetic tests for specificity of the purified anti-pCGH-1 polyclonal antibody preparation. Western blot of wild type (WT), mpk-1(0) and cgh-1(0) adult whole-worm lysates probed with anti-CGH-1 total antibody (gift of D. Greenstein, University of Minnesota) (top), the anti-pCGH-1 antibody preparation after four rounds of affinity purification (middle) and anti-tubulin antibody (bottom). Probing with anti-total CGH-1 reveals a closely spaced doublet (*, upper band, #, lower band) in wild-type worms in which both bands are absent in cgh-1(0). Probing with anti-pCGH-1 reveals a single band (*) in wild-type worms, which is absent in cgh-1(0) , indicating that the anti-pCGH-1 antibody preparation is specific for CGH-1. In mpk-1(0) , the anti-pCGH-1 preparation fails to detect a band, indicating that the antibody is specific to MPK-1 ERK-mediated phosphorylation of CGH-1. The slower migrating band (*) in the wild type recognized by anti-total-CGH-1 is probably phospho-CGH-1, as it is absent from the mpk-1(0) lysate and comigrates with the single band recognized by the anti-pCGH-1 antibody preparation (data not shown), whereas the bottom band (#) is probably unphosphorylated CGH-1 as it is present in the mpk-1(0) lysate and absent after staining with the anti-pCGH-1 antibody preparation. 
Tubulin times, although this will be highly dependent on the duration of storage. Storage should not be more than 3 months from the time of making the column. Longer storage times result in decreased efficacy of purification.
Scaling of the protocol and materials. The amount of serum that will be used to purify the phosphopeptide-specific antibody will determine the size of the peptide column that is made, the amount of starting peptide, the amount of maleimide-activated BSA, the amount of CNBr-activated Sepharose and the resulting column bed volume and the number of fractions collected ( Table 3) . The procedure here assumes that 1-2 ml of crude serum will be used; if a larger amount is to be used, then scale up each component as indicated ( Table 3) . 
MaterIals

REAGENTS Reagents as part of kits used in the protocol
Phosphopeptides (and corresponding non-phosphopeptides)
Custom peptides (designed as described in Experimental design) can be made in-house or they can be obtained from commercial vendors; it is recommended that at least 20 mg of the phosphopeptide and 20 mg of the non-phosphopeptide be synthesized, followed by HPLC purification to >90% purity. We have stored the peptides in powdered form from the manufacturer at −20 °C and weighed out material as needed  crItIcal The peptide powder is hydroscopic. Warm the vial containing the peptide powder to room temperature (22 °C) before opening it  crItIcal Avoid, if possible, internal cysteine in the peptide immunogen, as it may form a disulfide bond with the terminal cysteine, thus reducing the efficiency of conjugation to KLH and BSA. If an internal cysteine is unavoidable, then the terminal cysteine should be placed on the adjacent end.
Polyclonal antisera
Custom polyclonal antisera (e.g., rabbit) are generated with the 2 mg of KLH-conjugated sera phosphopeptide through a commercial vendor or in-house (as described in the Experimental Design). We have used several different vendors such as Open Biosystems, Covance and Yenzyme. We have SDS sample buffer, 2× Add 2.5ml of 0.5 M Tris-HCl (pH 6.8), 2 ml of glycerol, 4 ml of 10% (wt/vol) SDS and 0.5 ml of 0.1% (vol/vol) bromophenol blue. Bring the volume to 10 ml. Store the buffer at room temperature for up to 1 year. Add 1% (vol/vol) β-mercaptoethanol to the 2× SDS sample immediately before use. The shelf-life of this buffer is 1 week. SDS, 10% (wt/vol) For 1 liter of 10% (wt/vol) SDS, dissolve 100 g of sodium lauryl sulfate in 800 ml of deionized solution. Heat the solution to ~37 °C to facilitate dissolution. Care must be taken to ensure that the solution does not over-bubble. Make up the volume to 1,000 ml. Store the solution at room temperature for up to 1 year. Tris-glycine SDS, 5× For 1 liter, dissolve 15.1 g of Tris base and 94 g of glycine in 800 ml of deionized water. Once the solution has fully dissolved, add 50 ml of 10% (wt/vol) SDS and dissolve it gently to avoid excessive bubbling. Make up the volume of the solution to 1,000 ml. Store the solution at room temperature for up to 1 year. Coomassie Brilliant Blue Dissolve 1 g of Coomassie Brilliant Blue powder in 200 ml of methanol and 3.5 ml of glacial acetic acid made up to a final volume of 500 ml with deionized water. Store the solution at room temperature for up to 1 year. ! cautIon Glacial acetic acid is a strong acid, and it should be used in a fume hood; wear goggles, gloves and a lab coat. Pipette out the acid by using a glass pipette to avoid plastic corrosion. Coupling buffer (Also called alkaline wash buffer when used for washing peptide columns) Mix 0.1 M NaHCO3 and 0.5 M NaCl. Adjust the pH to 9.5 with 50% (wt/vol) NaOH. For 1 liter, dissolve 8.4 g of NaHCO3 and 29.2 g of NaCl in 800 ml of deionized water. Adjust the pH to 9.5. Make up the volume to 1,000 ml. Store the buffer at room temperature for up to 1 year. ! cautIon The strong base should be used in a fume hood; wear goggles, gloves and a lab coat. Pipette out the acid by using a glass pipette to avoid corrosion of plastic. Column wash buffer (also called acidic wash buffer when used for washing peptide columns) Column wash buffer is 0.1 M sodium acetate (pH 4.0) and 0.5 M NaCl. For 1 liter, dissolve 5.25 ml of glacial acetic acid and 29.2 g of NaCl in 800 ml of deionized water. Adjust the pH with 50% NaOH. Store the buffer at room temperature for up to 1 year. ! cautIon The strong base
should be used in a fume hood; wear goggles, gloves and a lab coat. Pipette out the acid by using a glass pipette to avoid corrosion of plastic. Blocking buffer Blocking buffer is 0.5 M NaCl, 20 mM Tris (pH 8.0) and 0.05% (vol/vol) Tween-20. For 1 liter, dissolve 29.2 g of NaCl and 2.42 g of Tris Base in 800 ml of deionized water. Adjust the pH of the solution to 8.0 with HCl. Add 50 µl of Tween-20 to the solution. Add 1% (wt/vol) sodium azide (1 g in 100 ml of deionized water) to the entire amount at 0.02%, or to a smaller aliquot. The shelf life of blocking buffer is 1 month at room temperature. ! cautIon HCl is a strong acid and it should be used in a fume hood; wear goggles, gloves and a lab coat. Pipette out the acid by using a glass pipette to avoid corrosion of plastic. ! cautIon Sodium azide is toxic, and it should be used in a fume hood; wear goggles, gloves and a lab coat. Pipette out the acid by using a glass pipette to avoid corrosion of plastic. NaCl, 100 mM For 1 liter, dissolve 5.84 g of NaCl in 1,000 ml of deionized water. Store the solution at room temperature for up to 1 year. HCl, 10 mM Add 86 µl of concentrated HCl to 100 ml of deionized water. proceDure conjugating peptides to maleimide-activated bsa • tIMInG 2-4 h 1| Weigh out 2 mg of the peptide (either the non-phosphopeptide, for the subtraction, or the phosphopeptide for the affinity purification) and dissolve it in 200 µl of conjugation buffer.
2|
If some peptide remains undissolved (solution is turbid), add DMSO to a final concentration of 1% (vol/vol) to the mixture to increase solubilization, and continue rotation at room temperature for 1 h.
3|
Centrifuge the mixture at 8,000g at 4 °C for 2 min and collect the supernatant for use in Step 5; the precipitate is undissolved peptide and should be discarded. If it is not removed, this peptide will disrupt the conjugation efficiency and also clog the desalting column (below).
4|
Add 200-500 µl of conjugation buffer to the maleimide-BSA tube.
5|
Add the dissolved peptide (supernatant from Step 3) to the tube from Step 4.
6|
Rotate the tubes on an invert rotator at room temperature for 2 h.  crItIcal step Both peptide and BSA should be fully dissolved before proceeding.
Desalting the peptide-bsa conjugated mix • tIMInG 30 min-1 h 7| Add 60 ml of deionized water to one bottle of purification salts.
8|
Dissolve the salts in water by vortexing the mix.
9| Add DMSO to a final concentration of 1% (vol/vol), if DMSO was used in Step 2.
10| Add 500 µl-1 ml of this purification buffer to one desalting column and let it drain by gravity.
11| Add 500 µl of purification buffer each time to the column and repeat Step 10 three times.
12| Label ten 1.5-ml Eppendorf tubes and have it ready for fraction collection.
13|
Add the peptide-BSA mix from Step 6 to the top of the column and drain the flow-through and discard it.
14| Add 500 µl of the purification buffer to the center of the column (on top) and collect the fraction in one of the tubes from Step 12.
15| Repeat
Step 14 nine additional times to collect the ten fractions.
16|
Measure the absorbance of each of the fractions at 280 nm to assess for the presence of peptide-BSA mix. Combine all the fractions with a positive OD value.
17|
Determine the peptide-BSA concentration either by using the 280-nm wavelength and the Warburg-Christian method for protein detection 80 , the BCA protein quantification method 81 or any preferred method of protein quantification. It is essential to know the protein concentration per ml for subsequent antibody purification step, Step 34.
assessing the efficiency of peptide-bsa conjugation • tIMInG 5-6 h 18| Add 10 µl of 2× SDS sample buffer to 10 µl of peptide-BSA mix from Step 16.
19|
Boil the mixture at 100 °C for 1 min in a boiling water bath.
20|
Centrifuge the mixture at 8,000g at 22 °C for 2 min and let it sit at room temperature for 5 min.
21|
Load the entire amount on a 10% (wt/vol) SDS-PAGE gel and run it with a protein marker at 80 V (for more details, see ref. 82 ).
22|
Stain the gel for protein visualization with Coomassie Brilliant Blue (for more details, see ref. 82 ). The conjugated peptide-BSA complex runs at a higher molecular weight (Fig. 4) compared with the unconjugated BSA.
? troublesHootInG
Dialysis of peptide-bsa complex into coupling buffer for column preparation • tIMInG 16 h at 4 °c 23|
Add the peptide-BSA complex (maximum of 5 ml volume) to the 10-kDa Slide-a-Lyzer cassettes.
24|
Place the cassette in 4-liter beaker, with stir bar, containing coupling buffer and dialyze it overnight at 4 °C.
25|
The next morning, remove the liquid from the Slide-a-Lyzer; there should be no precipitate formation. Remove 5 µl of the dialyzed peptide-BSA complex and check the pH of the solution with pH paper to ensure that the mixture is at a pH of 9.0. If the pH is lower, add more coupling buffer until the pH is at 9.0. Store the solution at 4 °C until use.
coupling non-phosphopeptide and phosphopeptide-bsa to sepharose • tIMInG 1 d 26| Weigh out 0.3 g of CNBr-Sepharose for a 1-ml bed volume column (table 3, row 1), in a disposable 15-ml polypropylene conical tube.
27| Add 7 ml of 10 mM HCl to the CNBr-Sepharose powder.
28|
Mix it on an invert rotator at room temperature for 60 min at room temperature.
29|
Set up a Bio-Rad Econo-Pac column by breaking off the bottom and attaching a small stopcock provided with the columns.
30| Add 10 ml of 10 mM HCl to the column and let it drip through by gravity; repeat three times.
31|
Add the swollen CNBr-Sepharose resin (from Step 28) to the column and keep the stopcock closed. Open the stopcock and add 90 ml of 10 mM HCl and allow it to drip through with gravity.
32| Add 10 ml of coupling buffer to the column and let it drip through.  crItIcal step This step activates the resin, and thus it should only be carried out when the peptide-BSA solution is ready to use.
33|
Close the stopcock at the bottom before the last of the buffer drips through. Remove 10 µl of the Sepharose with a pipette and save it in an Eppendorf tube for processing at Step 40.
34| Add the dialyzed peptide-BSA mixture from Step 25 to the column. Given the capacity of the CNBr-Sepharose, use no more than 2 mg of the peptide-BSA mix with 1 ml of resin.
35|
Fill up the column with coupling buffer.
36|
Cap the top of the column.
37|
Gently invert-rotate the column with the resin, peptide-BSA mixture and the buffer at room temperature for 1 h. ! cautIon In all cases in which columns are being inverted-rotated, the closed stopcock at the bottom and the cap on the top should also be sealed with a Parafilm wrap to prevent inadvertent loss of liquid. Additionally, care should be taken to ensure that the resin does not stick to the side of the column and dry out by adding more of the buffer used to load the column. In this case, drying out will cause less peptide-BSA to be coupled to the column, resulting in a column that has a lower capacity for binding to the antibodies.
38|
Continue mixing of the contents of the column at 4 °C overnight on a rotating shaker or drum.
39|
Remove the stopcock at the bottom and the cap at the top and allow the peptide-BSA to drip through. Save 100 µl of the flow-through for assessment of coupling efficiency between the peptide-BSA mix and the Sepharose in Step 40. The Sepharose conjugated to the peptide-BSA complex will reveal protein bands on the gel, whereas Sepharose unconjugated to protein beads will not reveal any protein bands on the gel. ? troublesHootInG 42| Add 10 ml of alkaline wash buffer to the column from Step 39. Let it drip through, and then discard it.
40|
43| Add 10 ml of acidic wash buffer to the column. Let it drip through, and then discard it.
44|
Repeat Steps 42 and 43 five more times.
45| Add 10 ml of blocking buffer to the column. Let it drip through, and then discard it. Repeat this five times.
46|
Add 0.2% (wt/vol) sodium azide in 4 ml of blocking buffer to the column for future storage. The column can be stored up to 3 months at 4 °C. ! cautIon For all uses of the peptide columns, at no point should the column be allowed to completely dry. Always leave a small amount of buffer behind.
subtracting the non-phosphopeptide antibodies from the crude serum • tIMInG 1 d 47| Thaw 1-2 ml of crude immune serum (for a 1-ml column) on ice.
48|
Remove large debris by spinning the serum in a clinical centrifuge or microcentrifuge at 4 °C at 2,000g for 3 min and remove small particulate matter by using a 0.45-µm syringe filter.
49|
Dilute the serum 1:10 with chilled 100 mM NaCl. Keep it on ice.
50|
Remove the non-phosphopeptide column from 4 °C.
51|
Add 20 ml of 100 mM NaCl to the column and let it drip by gravity, and discard the flow-through.
52|
Close the stopcock and add the diluted serum to the column, and ensure that there is not much space on top.
53|
Cap and Parafilm-wrap the column.
54|
Incubate the column on a rotator/shaker at 4 °C overnight, with gentle agitation.
55|
The next morning, collect the flow-through from the column.  crItIcal step The flow-through is the set of antibodies that did not bind to the non-phosphopeptide column, and it represents, at least in part, the antibodies that are specific to the phosphopeptide and that will next be passed over the phosphopeptide column.
56|
Add 5 ml of 100 mM NaCl to the column and collect the flow-through.
57|
Combine the flow-throughs from Steps 55 and 56 and place them on ice at 4 °C.
affinity-purifying phosphopeptide antibodies from fraction subtracted with the non-phospho column • tIMInG 1 d 58| Remove the phosphopeptide column from 4 °C.
59|
Let the storage solution drip through the column after opening the stopcock and cap.
60| Add 20 ml of 100 mM NaCl to the column and let it drip by gravity, and discard the flow-through.
61|
Close the stopcock and add the flow-through collected from the non-phosphopeptide column (from Step 57) to the phosphopeptide column. Cap and Parafilm-wrap the column.
62|
Gently invert-rotate the column on a rotator/shaker or drum overnight at 4 °C.
63|
The next morning, continue the incubations at room temperature for 1 h and then let the flow-through drip through the column; collect the flow-through.
64|
Save the flow-through from the phosphopeptide column at 4 °C; if necessary, it can be tested to determine the efficacy of the binding of the antibodies to the phosphopeptide column.
stringent washing of the phosphopeptide column • tIMInG 1 h 65| Add 10 ml of 10 mM Tris (pH 7.5) and 0.5 M NaCl to the column and let it drip through the column, and then discard it.
66|
Repeat this step three times.
67| Add 10 ml of alkaline wash buffer (pH 9.5) to the column. Let it drip through, and then discard it.
68| Add 10 ml of acidic wash buffer (pH 4.0) to the column. Let it drip through, and then discard it.
69|
Repeat Steps 67 and 68 three additional times. Note that PVDF should not be used.
75|
Let the spots dry completely at room temperature.
76|
Place the membrane in a flat plastic dish.
77|
Add WBBB and place the membrane on a horizontal platform rotator/shaker at room temperature for 30 min.
78| After 30 min, discard the WBBB and wash the membrane three times in WBBB for 5 min each, discarding the liquid after each wash.
79|
Incubate the membrane in WBBB containing secondary antibody conjugated to HRP or alkaline phosphatase (as needed) for 30 min at room temperature.  crItIcal step The secondary antibody should be specific to species of the antibody being purified (in the case of the rabbit anti-pCGH-1, it is an anti-rabbit IgG secondary antibody).
80|
Wash the membrane three times for 10 min each with WBWB.
81|
Develop it with the ECL reagent as per the manufacturer's instructions.
? troublesHootInG 82| Pool all the fractions that are positive for IgG in Step 81 ( Fig. 7) .
testing purified antibodies for phosphopeptide specificity • tIMInG 3 h 83| Dissolve 10 µg µl −1 of the phosphopeptide and non-phosphopeptide, each in sterile deionized water.
84| Spot 1 µl each of the non-phosphopeptide and the phosphopeptide from Step 83, in serial dilutions of 1 µg, 100 ng, 10 ng, 1 ng and 0.1 ng onto the same strip of nitrocellulose.
85|
Let the spots dry.
86|
Incubate the membrane in WBBB for 30 min at room temperature.
87|
Discard the blocking buffer and wash the membrane three times for 5 min each in WBWB.
88| Dilute the pooled, neutralized phospho-antibody column eluate from Step 72 1:1,000 in WBBB and add 10 ml to the nitrocellulose membrane.
89|
Incubate the membrane on a rotator at room temperature for 1 h.
90|
Discard the solution containing the diluted primary antibody.
91|
Wash the membrane three times in WBWB for 5 min each.
92| Proceed as detailed in
Step 81.
93|
If the purified phospho-antibody preparation has reactivity to the non-phosphopeptide in the dot blot (Fig. 5) , then pass the pooled antibody fractions (Step 82) over the non-phosphopeptide column for an additional round of subtraction (Steps 50-57; Fig. 2, g→b) ; the number of fractions pooled in Step 82 will depend on the efficiency of elution-make up to a total volume of 15 ml by adding 100 mM NaCl before loading on to the non-phosphopeptide column in
Step 52 (as a replacement for loading the diluted serum).  crItIcal step Columns must be regenerated (Steps 104-110) before use in additional rounds of purification. ? troublesHootInG testing purified antibodies for phosphoprotein specificity • tIMInG 1 d 94| If, as expected, the purified phospho-antibody preparation detects the phosphopeptide in the dot blot (Step 93; Fig. 5 ), then test it for specificity (i.e., effectiveness of removal of antibodies that recognize low-sequence-complexity concentrating purified polyclonal antibody and storage • tIMInG 1 h concentration, 16 h dialysis 111| Add 10 ml of pooled purified phospho-antibody from Step 82 to a 10-kDa Amicon concentrator (Millipore).
112|
Spin the tubes at 4,000g for 45 min in a high-speed centrifuge at 4 °C.
113|
With extreme care and without disturbing the membrane draw out the reduced, concentrated antibody from the top of the membrane, usually 100-400 µl of antibody-containing solution.
114| Determine the antibody concentration by using a spectrophotometer.
115|
Dialyze the antibody into 1× PBS overnight at 4 °C by using the Dialyzer cassettes.
116|
Add to a final concentration of 2.5% (wt/vol) BSA, 0.01% (vol/vol) Tween-20 and 25% (vol/vol) glycerol to the concentrated dialyzed antibody for long-term storage.
purifying polyclonal antibodies to fusion proteins; making the columns with recombinant protein • tIMInG 2 d 117| Dialyze 500 µg ml −1 of purified recombinant protein into coupling buffer. Typically, 500 µg mg −1 of a fusion protein is used for coupling to 1 ml of Sepharose.
118| Perform Steps 26-28.
119|
Add the swollen resin to a Bio-Rad Econo-Pac column as described in Steps 29 and 30.
120| Add 20 ml of 10 mM HCl to the column and let it drip through.
121| Add 5 ml of coupling buffer to the column and let it drip through.
122| Add 1 ml of the recombinant protein solution from
Step 117 to the column from Step 121.
123| Perform Steps 35 and 36.
124| Incubate the column with the protein and Sepharose at 4 °C overnight on a rotating shaker.
125|
The next morning, at room temperature, let the protein solution drip through from the column.
126| Add 10 ml of coupling buffer to the column and let it drip through.
127| Add 10 ml of column wash buffer to the column and let it drip through.
128| Perform Steps 65-69. ! cautIon Do not allow the solution to collect in the column at any point by plugging the column. Allow for a steady flow rate.
129| Add 50 ml of blocking buffer to the column, and let it drip through.
130| Perform
Step 46 for column storage and future use. 133| Remove the affinity column (from Step 130) from 4° C and prewash the column with 20 ml of 100 mM NaCl.
134| Add the diluted crude serum from
Step 132 to the column, and care should be taken to close the column with the stopcock.
135| Perform Steps 53 and 54.
136|
The next morning, open the stopcock and the cap and let the solution drip through, and then discard it.
137| Add 4 × 20 ml of 10 mM Tris (pH 7.5) and 0.5 M NaCl to the column and let it drip through, and then discard it.
138|
Perform stringent washes as in Steps 65-69. • tIMInG The total time for the purification procedure from start to finish is 5 d and 7 h, owing to multiple overnight incubation steps. Instead of using the flow through from the non-phosphopeptide column, the elution from the nonphosphopeptide column was used for binding to the phosphopeptide column
139|
Ensure that the flow-through from the non-phosphopeptide column is the one used to pass over the phosphopeptide column
The phosphopeptide column was not washed thoroughly and coupled during preparation with the coupling buffer and wash buffer, resulting in some phosphopeptides coming off the column during antibody elution Prepare the phosphopeptide column again, with care taken to follow each step of the protocol
The secondary antibody used for blotting is old and does not work
Use a positive control sample to ensure that the secondary antibody works ECL kit used was left out at room temperature and the reagent is not optimal
Use a positive control sample to ensure that the ECL reagent is optimally functioning
93
The phosphopeptide antibody preparation also recognizes the non-phosphopeptide Refer to Figure 1 for possible options for the types of antibodies that can be generated from the phosphopeptide immunogen Pass the antibody back over the nonphosphopeptide column and collect the flow-through that is then passed over the phosphopeptide column
antIcIpateD results
To generate modified protein-specific polyclonal antibodies, multiple rounds of subtraction and affinity purification are usually necessary. As shown by dot blotting (Fig. 5) , two rounds of subtraction for the anti-pCGH-1 antibody were necessary to remove antibodies that bound to the unmodified peptide. Four rounds of affinity purification with stringent washes were required to remove antibodies that reacted with proteins other than pCGH-1, as assessed by western blots of wildtype adult hermaphrodite lysates (Fig. 3) . Genetic tests using western blots (Fig. 6) confirmed that the purified antibody preparation was specific to CGH-1, as no signal was detected from cgh-1-null mutant lysates, and that the phosphorylation event required MPK-1/ERK, as the pCGH-1 band was not detected in the mpk-1-null mutant. Immunocytochemistry of whole germ-line tissue shows that there is complete overlap between the cells that stain with purified pCGH-1 antibody and those that contain activated MPK-1/ERK (Fig. 8) , as expected, given that ERK is the kinase that phosphorylates CGH-1 on Ser67. Intriguingly, phosphorylation of CGH-1 alters the subcellular localization of the protein (Fig. 9) , illustrating one of the unique attributes of a modification-specific antibody reagent. Total CGH-1 is present in the cytoplasm of germ cells, as well as on perinuclear P granules 19, 83, 84 , which are germ-line granules that are thought to function in regulation of mRNA trafficking, translation and stability. We find that MPK-1/ERK phosphorylated CGH-1, while still present in the cytoplasm, 67 (dpMPK-1 in red, middle) and anti-phospho-CGH-1 (pCGH-1 in green, bottom), by using the antibody preparation after four rounds of affinity purification. pCGH-1 is only observed in germ cells that contain activated MPK-1, one of a number of criteria that indicate that the affinity-purified pCGH-1 preparation is specific (Figs. 3 and 6) . Asterisks (*) indicate the distal end of the germline. Scale bars, 20 µm. (Fig. 8) . Total CGH-1-specific staining (a) highlights P granules (arrowheads) that surround nuclei, as well as cytoplasmic and weaker nuclear staining. In contrast, pCGH-1-specific staining (b) does not highlight P granules, whereas the cytoplasmic and weak nuclear staining remains. The antibody specific to pCGH-1 fails to stain cgh-1(0) (d), indicating that the antibody is specific to CGH-1 and fails to stain cgh-1(tn691ts) (c), which is a missense mutation in the proline (Pro68Leu) that is C terminal to phosphorylated Ser67 and thus not expected to be phosphorylated in the mutant. Scale bars, 40 µm.
